Ab interno trabeculotomy combined with cataract extraction in eyes with primary open-angle glaucoma

Yuan-Zhi Chen¹, Ai-Ping Song², Wen-Yan Jin¹, Xiao Yang¹ and Guang-Fu Dang²

Abstract
Objective: To investigate the efficacy and safety of ab interno trabeculotomy using the VISCO360® Viscosurgical System (Sight Sciences, Inc., Menlo Park, CA, USA) combined with cataract extraction in the treatment of primary open-angle glaucoma (POAG).
Methods: Patients with POAG who underwent ab interno trabeculotomy combined with cataract extraction were retrospectively analyzed. Best-corrected visual acuity (BCVA), intraocular pressure (IOP), the number of antiglaucomatous medications, and complications were recorded preoperatively and 1 week, 1 month, 3 months, 6 months, 1 year, and 2 years postoperatively.
Results: Thirty-four patients (40 eyes) with POAG were included in this study, including 20 men (22 eyes) and 14 women (18 eyes). Compared with the preoperative IOP, the postoperative IOP was significantly lower at each time point. The greatest reduction in IOP was 60.7% at 1 month after surgery. The BCVA was also significantly improved at each postoperative time point. The number of antiglaucomatous medications used by the patients was significantly lower postoperatively than preoperatively.
Conclusion: Ab interno trabeculotomy combined with cataract extraction is effective and safe for treatment of POAG.

Keywords
Trabeculotomy, glaucoma, VISCO360®, cataract extraction, intraocular pressure, best-corrected visual acuity

Date received: 2 March 2020; accepted: 12 August 2020
Introduction

Glaucoma has been classified as the second most common cause of blindness by the World Health Organization. The number of patients with glaucoma worldwide is estimated to increase to 80 million by 2020. Of these patients, 74% are expected to have primary open-angle glaucoma (POAG). By 2040, the total number of patients with glaucoma worldwide will reach an estimated 111.8 million. Reducing the intraocular pressure (IOP) is currently the only effective treatment for glaucoma. Trabeculectomy combined with antimetabolites remains the classic procedure in the surgical treatment of glaucoma. However, as a bleb-dependent procedure, trabeculectomy often fails because of scarring of the filtration passage and poor formation of functional filtration blebs. Therefore, many glaucoma physicians seek non-bleb-dependent filtering techniques; i.e., new surgical methods that divert or restore normal aqueous humor pathways to drain aqueous humor or increase outflow from physiological pathways.

Trabeculotomy is a newly developed operation aimed at the level of Schlemm’s canal and the trabecular meshwork. By expanding Schlemm’s canal and cutting the trabecular meshwork and the inner wall of Schlemm’s canal, a natural channel of aqueous humor outflow can be created. This operation can avoid the problems of conjunctival scarring and filtration bleb-related complications. Trabeculotomy is more in line with the characteristics of minimally invasive glaucoma surgery, giving it good prospects for clinical application.

In this study, we retrospectively analyzed the efficacy and safety of trabeculotomy using the VISCO360® Viscosurgical System (Sight Sciences, Inc., Menlo Park, CA, USA) combined with cataract extraction in patients with POAG. Our aim is to report the surgical outcomes of this new procedure in a consecutive case series.

Methods

This study was approved by the Ethics Committee of the Shandong Provincial Qianfoshan Hospital and was performed in accordance with the Helsinki Declaration. Written informed consent was obtained from all patients.

Patients who had POAG and underwent ab interno trabeculotomy combined with cataract extraction from January 2017 to June 2017 in the Department of Ophthalmology, Shandong Provincial Qianfoshan Hospital were included in this retrospective study. These patients either had insufficiently controlled IOP or could not tolerate long-term medication. The indication for cataract extraction was the presence of a visually significant cataract coexisting with glaucoma.

The exclusion criteria were types of glaucoma other than POAG, the presence of other intraocular diseases (e.g., lens dislocation or retinal detachment), and a history of eye surgery (e.g., antiglaucoma surgery or cataract surgery).

Surgical procedures

All surgical procedures were performed by the same senior doctor. Ab interno trabeculotomy was performed after cataract extraction, and implantation of a hydrophobic acrylic foldable intraocular lens was successfully completed. A microcatheter was introduced into the anterior chamber by way of a single, self-sealing, 2.4-mm clear corneal incision made for cataract extraction. Using an anterior chamber angle mirror to determine the position of the trabecular meshwork, the VISCO360® cannula was aligned with the incision and inserted into Schlemm’s canal for 360° expansion. As the microcatheter continued to exit the...
anterior chamber, the trabecular meshwork and the inner wall of Schlemm’s canal were cut for 360°.

Postoperative evaluation

Best-corrected visual acuity (BCVA), IOP (Goldmann tonometer), the number of antiglaucomatous medications, and complications were analyzed preoperatively and 1 week, 1 month, 3 months, 6 months, 1 year, and 2 years postoperatively. The efficacy endpoint was the mean reduction in IOP from baseline. Safety measures were the rate of adverse events (intraoperative and postoperative) and re-interventions to treat glaucoma. The criteria for success were a postoperative IOP of ≤15 mmHg (criterion A) or ≤12 mmHg (criterion B) without an increase in the number of IOP-lowering medications at or after 6 months of follow-up. IOP values measured within 3 months postoperatively were not considered to indicate surgical failure because the occurrence of postoperative IOP fluctuations after trabeculotomy is well known. All decimal visual acuity values were converted to the logarithm of the minimum angle of resolution (logMAR) for analyses.

Statistical analysis

The statistical analysis was performed using IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., Armonk, NY, USA). The paired t-test was used to compare BCVA, IOP, and the number of antiglaucomatous medications before and after surgery. A P value of <0.05 was considered statistically significant.

Results

Thirty-four patients (40 eyes) with POAG were included in this study. The patients comprised 20 men (22 eyes) and 14 women (18 eyes) with a mean age of 68 ± 7.58 years.

Preoperative and postoperative IOP

The preoperative and postoperative IOP of the patients are shown in Table 1. Figure 1 shows the mean IOP at each follow-up time point, and the vertical lines represent the standard errors. The postoperative IOP at each time point was significantly different from the preoperative IOP (P < 0.05). Compared with the preoperative results, the IOP was markedly lower at 1 week after the operation. The lowest IOP occurred 1 month after operation, and the reduction rate of IOP was 60.1%. The surgical success rate at 6 months and 2 years after surgery was 100% for criterion A and 65% for criterion B.

Preoperative and postoperative BCVA

Preoperative and postoperative BCVA of the patients are shown in Table 2. Figure 2 shows the mean BCVA at each follow-up time point, and the vertical lines represent the standard errors. Compared with the preoperative BCVA, the BCVA was improved at each postoperative time point, and the difference was statistically significant (P < 0.01). The best vision was achieved 3 months after the operation, and the patients’ vision remained stable after 2 years of follow-up.

Preoperative and postoperative antiglaucomatous medications

Table 3 shows the number of antiglaucomatous medications before and after surgery. Figure 3 shows the average number of antiglaucomatous medications used before and after surgery at each follow-up time point, and the vertical lines represent the standard errors. The number of antiglaucomatous medications was significantly lower after surgery than before surgery, and the difference was statistically significant (P < 0.01). The patients were using the fewest IOP medications at 3 months postoperatively.
The number of antiglaucomatous medications remained stable during the 2-year follow-up.

**Complications**

One patient developed a small amount of anterior chamber hemorrhage during the operation, and the blood absorbed within 1 day postoperatively. The postoperative complications examined in this study were hyphema, a shallow anterior chamber, choroidal detachment, endophthalmitis, lens subluxation, and hypotony (IOP of <5 mmHg). None of these postoperative complications developed in any eyes.

---

**Table 1.** Preoperative and postoperative intraocular pressure (mmHg).

|                      | Preoperatively | 1 week | 1 month | 3 months | 6 months | 1 year | 2 years |
|----------------------|---------------|--------|---------|----------|----------|--------|---------|
| **Mean**             | 28.75         | 13.3   | 11.4    | 11.5     | 11.5     | 11.5   | 11.5    |
| **Standard deviation**| 6.98         | 6.05   | 2.56    | 2.29     | 2.26     | 2.26   | 2.28    |
| **Minimum**          | 15            | 7      | 7       | 8        | 8        | 8      | 8       |
| **Maximum**          | 45            | 30     | 15      | 15       | 15       | 15     | 15      |
| **P**                | <0.01         | <0.01  | <0.01   | <0.01    | <0.01    | <0.01  | <0.01   |

**Figure 1.** Preoperative and postoperative IOP.

IOP, intraocular pressure; preo, preoperatively; w, week; m, month, y, year.

**Table 2.** Preoperative and postoperative best-corrected visual acuity.

|                      | Preoperatively | 1 week | 1 month | 3 months | 6 months | 1 year | 2 years |
|----------------------|---------------|--------|---------|----------|----------|--------|---------|
| **Mean**             | 0.25          | 0.39   | 0.49    | 0.52     | 0.52     | 0.52   | 0.52    |
| **Standard deviation**| 0.14         | 0.15   | 0.13    | 0.15     | 0.15     | 0.15   | 0.15    |
| **Minimum**          | 0.05          | 0.12   | 0.2     | 0.25     | 0.25     | 0.25   | 0.25    |
| **Maximum**          | 0.5           | 0.6    | 0.6     | 0.8      | 0.8      | 0.8    | 0.8     |
| **P**                | <0.01         | <0.01  | <0.01   | <0.01    | <0.01    | <0.01  | <0.01   |
Despite the new progress that has been made in the pathogenesis of glaucoma during the past few decades, surgeons still have few choices for the surgical treatment of glaucoma. Trabeculectomy is still considered the main treatment for glaucoma. Although the effect of trabeculectomy is good, it is associated with many complications such as filtration bleb scarring, late filtration bubble leakage, filtering blebitis, endophthalmitis, and low IOP.\textsuperscript{5} To avoid complications of filtering surgery and reducing injuries, reconstructing the natural passage of aqueous humor outflow is the ultimate goal of glaucoma surgery. Establishing the aqueous humor outflow channel is an important part of ab interno trabeculotomy and one of the most effective surgical procedures.

Structural changes of Schlemm’s canal play an important role in the occurrence and development of glaucoma. Age and IOP are important factors that can influence the structure of Schlemm’s canal. Ainsworth and Lee\textsuperscript{6} found that the length of the inner wall of Schlemm’s canal decreased with age. By observing specimens of trabecular tissue removed from patients with glaucoma, Lee\textsuperscript{7} found that a small stenosis of Schlemm’s canal was present in 50% of cases. Allingham et al.\textsuperscript{8} found that the length of Schlemm’s canal and the inner wall were significantly smaller in eyes with

**Figure 2.** Preoperative and postoperative BCVA.

BCVA, best-corrected visual acuity; preo, preoperatively; w, week; m, month; y, year.

**Table 3.** Number of preoperative and postoperative antiglaucomatous medications.

|                | Preoperatively | 1 week | 1 month | 3 months | 6 months | 1 year | 2 year |
|----------------|----------------|--------|---------|----------|----------|--------|--------|
| Mean           | 2.6            | 0.85   | 0.35    | 0.1      | 0.1      | 0.1    | 0.1    |
| Standard deviation | 0.73          | 1.01   | 0.57    | 0.3      | 0.3      | 0.3    | 0.3    |
| Minimum        | 1              | 0      | 0       | 0        | 0        | 0      | 0      |
| Maximum        | 4              | 3      | 2       | 1        | 1        | 1      | 1      |
| \( P \)        | \(<0.01\)     | \(<0.01\) | \(<0.01\) | \(<0.01\) | \(<0.01\) | \(<0.01\) | \(<0.01\) |
than without glaucoma. A study of the effect of IOP on the diameter of Schlemm’s canal showed that when the IOP increased, the lumen of Schlemm’s canal narrowed, and the trabecular meshwork protruded into the lumen of Schlemm’s canal, at 40 mmHg (1 mmHg = 0.133 kPa), most of Schlemm’s canal collapsed. Narrowing or collapse of Schlemm’s canal is not only caused by an increase in IOP but also reduces the outflow of aqueous humor, resulting in a further increase in IOP. In this study, by expanding Schlemm’s canal and cutting the trabecular meshwork and the inner wall of Schlemm’s canal, we removed obstacles at the level of the trabecular meshwork, facilitating treatment of POAG. Through the preliminary clinical observation in this study, we found that ab interno trabeculotomy combined with cataract extraction achieved the expected purposes: internal drainage, non-filtering bleb dependence, and stable surgical results. Three months after surgery, the mean IOP was 11.5 ± 2.28 mmHg, which was 60.1% lower than that before surgery, and the IOP was stable until 2 years after surgery. Khaimi showed that when phacoemulsification was combined with canaloplasty and successful suture placement, 27 eyes had a 42% mean decrease in IOP (23.5 ± 5.2 to 13.6 ± 3.6 mmHg). However, the postoperative IOP was lower in the present study, and the IOP was reduced to a greater extent, reaching 60.1%. Although intraoperative sutures are used to expand Schlemm’s canal and simple canaloplasty stretched the trabecular meshwork, the maintenance time is limited, and the long-term effect of reducing the IOP may be affected. Compared with simple canaloplasty, the procedure in this study removed the inner wall of Schlemm’s canal and part of the trabecular meshwork, directly removing the main resistance of the aqueous humor outflow. The outflow of aqueous humor does not depend on the trabecular meshwork. Better IOP reduction and a higher long-term success rate can be achieved. Bao et al. reported that after 6 years of follow-up, the success rate of trabeculotomy was 44%. The criterion for success was defined as IOP of <16 mmHg.
The follow-up time in the present study was 2 years. With extension of the follow-up time, the development of adhesions in the surgical area and changes in the success rate can be further verified in future studies.

For patients with glaucoma, there is a significant benefit in reducing the number of medications used to lower IOP. Long-term use of IOP-lowering drugs can cause damage to the ocular surface and increase the patient’s economic burden;\textsuperscript{13–16} it can also increase the chance of failure of filtration surgery.\textsuperscript{17} In the present study, the mean number of preoperative antiglaucomatous medications was 2.6 ± 0.73, and the mean number of antiglaucomatous medications 3 months after surgery was 0.1 ± 0.3. The number of antiglaucomatous medications decreased by 96.2\% 3 months after surgery. No new type of antiglaucomatous medication increased during the 2-year follow-up. This operation can effectively reduce the number of antiglaucomatous medications that are used in the long term.

Cataract is the most common eye disease in the elderly population. Approximately 33\% of patients worldwide are affected by blindness due to cataracts.\textsuperscript{18} In patients with glaucoma, cataract surgery can more effectively reduce the IOP and the number of antiglaucomatous drugs.\textsuperscript{19–21} Because elderly patients may have difficulties traveling frequently for hospital visits, they can be good candidates for trabeculotomy.\textsuperscript{22} In this study, the mean BCVA before surgery was 0.25 ± 0.15, and that 3 months postoperatively was 0.52 ± 0.15 (\textit{P} < 0.01). The patients’ visual acuity remained stable 2 years after surgery. This study demonstrated that ab interno trabeculotomy can be safely and effectively performed in combination with cataract extraction.

The results of this study showed that few postoperative complications occurred, and only one patient developed a small amount of anterior hemorrhage that was absorbed 1 day after surgery. Therefore, the results of this study indicate that ab interno trabeculotomy combined with cataract extraction is a safe procedure for patients.

Our data indicate that ab interno trabeculotomy combined with cataract extraction can be successfully performed in patients with POAG to facilitate aqueous humor outflow. After surgery, an ideal IOP was obtained and the number of antiglaucomatous medications was reduced. Because of its better IOP control and a lower rate of severe complications, ab interno trabeculotomy should undergo widespread utilization as a preferred surgical technique for POAG.

This study had certain limitations. It was a single-center with a relatively small sample size. Both eyes of some patients were included in the analysis when both eyes met the eligibility criteria. This is a potential confounder because of the lack of independence and should be considered in the interpretation of the results. Another limitation is the lack of morphological evaluation, such as assessment of postoperative changes in the surgical area. This was a retrospective and noncomparative case series, and the impact of cataract extraction on IOP cannot be ruled out.\textsuperscript{23} The results should be verified through future prospective randomized clinical controlled studies. Despite these limitations, we believe that this study provides important new insights into novel, less invasive canal reconstruction approaches to treat POAG.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
References
1. Quigley HA and Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* 2006; 90: 262–267.

2. Barkana Y and Dorairaj S. Re: Tham et al.: Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis (Ophthalmology 2014; 121: 2081-90). *Ophthalmology* 2015; 122: e40–e41.

3. Picht G and Grehn F. Classification of filtering blebs in trabeculectomy: biomicroscopy and functionality. *Curt Opin Ophthalmol* 1998; 9: 2–8.

4. Inatani M, Tanihara H, Muto T, et al. Transient intraocular pressure elevation after trabeculotomy and its occurrence with phacoemulsification and intraocular lens implantation. *Jpn J Ophthalmol* 2001; 45: 288–292.

5. Jin GJ, Crandall AS and Jones JJ. Phacotrabeculectomy: assessment of outcomes and surgical improvements. *J Cataract Refract Surg* 2007; 33: 1201–1208.

6. Ainsworth JR and Lee WR. Effects of age and rapid high-pressure fixation on the morphology of Schlemm’s canal. *Invest Ophthalmol Vis Sci* 1990; 31: 745–750.

7. Lee WR. Doyne Lecture. The pathology of the outflow system in primary and secondary glaucoma. *Eye (Lond)* 1995; 9: 1–23.

8. Allingham RR, De Kater AW and Ethier CR. Schlemm’s canal and primary open angle glaucoma: correlation between Schlemm’s canal dimensions and outflow facility. *Exp Eye Res* 1996; 62: 101–109.

9. Johnstone MA. Pressure-dependent changes in configuration of the endothelial tubules of Schlemm’s canal. *Am J Ophthalmol* 1974; 78: 630–638.

10. Battista SA, Lu Z, Hofmann S, et al. Reduction of the available area for aqueous humor outflow and increase in meshwork herniations into collector channels following acute IOP elevation in bovine eyes. *Invest Ophthalmol Vis Sci* 2008; 49: 5346–5352.

11. Khaimi MA. Canaloplasty: a minimally invasive and maximally effective glaucoma treatment. *J Ophthalmol* 2015; 2015: 485065.

12. Bao WJ, Kawase K, Huang H, et al. The long-term outcome of trabeculotomy: comparison with filtering surgery in Japan. *BMC Ophthalmol* 2019; 19: 99–107.

13. Feehan M, Munger MA, Cooper DK, et al. Adherence to glaucoma medications over 12 months in two US community pharmacy chains. *J Clin Med* 2016; 5: 79–87.

14. Kashiwagi K and Matsubara M. Reduction in ocular hypotensive eyedrops by ab interno trabeculotomy improves not only ocular surface condition but also quality of vision. *J Ophthalmol* 2018; 2018: 8165476.

15. Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. *Prog Retin Eye Res* 2010; 29: 312–334.

16. Rosin LM and Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. *Clin Ophthalmol* 2013; 7: 2131–2135.

17. Broadway DC, Grierson I, O’Brien C, et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. *Arch Ophthalmol* 1994; 112: 1446–1454.

18. Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. *Lancet Glob Health* 2013; 1: 339–349.

19. Samuelson TW, Chang DF, Marquis R, et al. A Schlemm’s canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. *Ophthalmology* 2019; 126: 29–37.

20. Zhang ML, Hirunyachote P and Jampel H. Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma.
21. Vold S, Ahmed II, Craven ER, et al. Two-year COMPASS trial results: supraciliary microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts. *Ophthalmology* 2016; 123: 2103–2112.

22. Tanito M, Sugihara K, Hara K, et al. Different glaucoma types and glaucoma surgeries among different age groups. *Graefes Arch Clin Exp Ophthalmol* 2018; 256: 2013–2014.

23. Hara K, Takai Y and Tanito M. Outcomes after combined deep sclerectomy and trabeculotomy to treat primary open-angle glaucoma and exfoliation glaucoma. *Shimane J Med Sci* 2019; 35: 43–52.